Drug Trial Radar · NCT06614621
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
43
Planned (sponsor's estimate)
Start
Feb 1, 2025
Primary completion
Dec 1, 2027
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- Fujian Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
Conditions
- Extensive-Stage Small Cell Lung Cancer
Interventions
Adebrelimab +Etoposide+Platinum-based drugsDrug
Adebrelimab:20mg/kg或1200mg ivgtt ,d1 ,Q3W Etoposide injection (E): 100mg/m2, ivgtt, d1,d2,d3,Q3W Platinum-based drugs:75mg/m2, ivgtt, d1,d2,d3,Q3W
Maintenance treatment period:Drug
Adebrelimab:20mg/kg或1200mg,IV, Q3W; Apatinib Mesylate Tablets:250mg,P.O,qod
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival(PFS)Time frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.